Providing credible, evidence-based information about medical technologies, treatments, and models of care
Attend a Meeting
CTAF will assess the comparative effectiveness and value of multiple new, all-oral direct-acting antiviral agent (DAA) regimens for the treatment of hepatitis C. The review will cover treatments under review by the FDA, including those developed by Gilead Sciences, Inc.
Sign up to receive email notifications of upcoming CTAF meetings and new assessments. All fields required.